PVLA - NASDAQ
Palvella Therapeutics, Inc.
$115.42
+10%Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
At a Glance
Live Snapshotpvla
Cash and Short Term Investments
Last Annual Value
57.98M
3-Year CAGR
53%
5-Year CAGR
-4%
10-Year CAGR
-2%
Palvella Therapeutics, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Palvella Therapeutics, Inc. NASDAQ:PVLA | 57.98M | 99.1% | -13.2% | N/A | |
 Tyra Biosciences, Inc. NASDAQ:TYRA | 256.00M | 8.0% | -3.3% | N/A | |
 ProKidney Corp. NASDAQ:PROK | 270.02M | -9.4% | 67.4% | N/A | |
 Kura Oncology, Inc. NASDAQ:KURA | 667.24M | 16.3% | 5.2% | 25.7% | |
 Savara Inc. NASDAQ:SVRA | 235.70M | 13.2% | 7.9% | 33.2% | |
 Rezolute, Inc. NASDAQ:RZLT | 167.86M | 18.1% | 32.5% | 45.1% | |
 ARS Pharmaceuticals, Inc. NASDAQ:SPRY | 244.99M | 2.4% | 32.5% | N/A | |
 Arbutus Biopharma Corporation NASDAQ:ABUS | 91.47M | -10.1% | -10.0% | -3.5% | |
 EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | 306.09M | -2.6% | 7.7% | 26.6% |
Palvella Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your PVLA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.